Stock listing

NASDAQ:KLRS Kalaris Therapeutics, Inc. Stock

Home listing (NASDAQ) of Kalaris Therapeutics, Inc.

Follow Kalaris Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:KLRS

$1.28 USD -0.09 (-6.6%)

Close on Nov 20, 2026

Past year -81.4% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.25 – $1.37 USDNov 20, 2026
Volume
37,986 sharesNov 20, 2026
Market cap
$30.47M USDAt the close on Nov 20, 2026 · price × 23.80M shares outstanding
52-week range
$1.25 – $11.88 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$201,311 USDMedian day 58,600 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Kalaris Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:KLRS · Home$1.28 USD-0.09 (-6.6%)37,986$1.31$1.37$1.25$1.37Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:KLRS · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.28-0.09-6.6%$1.31$1.37$1.2537,986
$1.37-0.06-4.2%$1.43$1.495$1.3553,156
$1.43-0.03-2.1%$1.46$1.55$1.33252,572
$1.46-0.115-7.3%$1.58$1.65$1.41157,336
$1.575-0.085-5.1%$1.64$1.696$1.5541,002
$1.66-0.24-12.6%$1.90$1.945$1.65200,281
$1.90+0.03+1.6%$1.90$1.98$1.84566,623
$1.87-0.43-18.7%$2.20$2.375$1.8081,438
$2.30-0.12-5.0%$2.49$2.50$2.2872,759
$2.42+0.06+2.5%$2.36$2.66$2.34197,850
$2.36+0.34+16.8%$2.01$2.46$1.94175,470
$2.02-0.03-1.5%$2.029$2.14$2.0128,386
$2.05+0.05+2.5%$2.09$2.14$2.0319,222
$2.00-0.03-1.5%$2.06$2.06$1.9259,274
$2.03-0.10-4.7%$1.98$2.08$1.96560,195
$2.13+0.12+6.0%$2.05$2.161$2.0523,166
$2.01+0.15+8.1%$1.86$2.02$1.8647,608
$1.86+0.06+3.3%$1.78$1.875$1.7850,126
$1.80-0.07-3.7%$1.90$1.90$1.7836,033
$1.87-0.12-6.0%$1.99$1.99$1.8725,400
$1.99-0.03-1.5%$2.01$2.04$1.9543,400
$2.02-0.05-2.4%$2.00$2.182$1.9584,400
$2.07+0.16+8.4%$1.90$2.10$1.9051,400
$1.91-0.09-4.5%$2.04$2.04$1.867271,500
$2.00-0.19-8.7%$2.25$2.292$2.0058,400
$2.19+0.06+2.8%$2.20$2.225$2.1057,000
$2.13-0.10-4.5%$2.22$2.23$2.1121,000
$2.23-0.03-1.3%$2.27$2.295$2.2073,300
$2.26-0.10-4.2%$2.37$2.37$2.22122,100
$2.36-0.14-5.6%$2.46$2.55$2.36104,400
$2.50-0.06-2.3%$2.60$2.60$2.35110,000
$2.56-0.10-3.8%$2.59$2.693$2.5374,100
$2.66-0.17-6.0%$2.90$2.93$2.61103,400
$2.83+0.13+4.8%$2.72$2.89$2.5827,400
$2.70-0.15-5.3%$2.90$2.90$2.51235,900
$2.85-0.04-1.4%$2.88$2.89$2.7658,600
$2.89-0.01-0.3%$2.87$2.97$2.75102,600
$2.90+0.055+1.9%$2.84$2.91$2.83551,800
$2.845-0.075-2.6%$2.91$2.97$2.8192,800
$2.92-0.15-4.9%$3.024$3.09$2.9149,300
$3.07-0.05-1.6%$3.13$3.162$3.0233,600
$3.12-0.12-3.7%$3.20$3.21$3.1224,000
$3.24-0.005-0.2%$3.225$3.285$3.1629,100
$3.245+0.045+1.4%$3.20$3.30$3.0988,600
$3.20+0.04+1.3%$3.18$3.23$3.04234,400
$3.16-0.02-0.6%$3.20$3.27$3.1343,300
$3.18-0.02-0.6%$3.15$3.25$3.1061,700
$3.20-0.10-3.0%$3.35$3.355$3.20109,400
$3.30-0.08-2.4%$3.41$3.445$3.2557,600
$3.38+0.08+2.4%$3.39$3.44$3.2795,100
$3.30-0.17-4.9%$3.55$3.66$3.3060,700
$3.47-0.16-4.4%$3.66$3.68$3.4583,000
$3.63-0.27-6.9%$3.88$3.90$3.60100,700
$3.90-0.04-1.0%$3.91$3.95$3.8223,900
$3.94+0.04+1.0%$3.97$4.04$3.90540,000
$3.90-0.02-0.5%$3.97$4.135$3.9016,400
$3.92-0.12-3.0%$3.96$4.00$3.8662,300
$4.04+0.01+0.2%$3.99$4.04$3.8319,600
$4.03-0.07-1.7%$4.12$4.15$3.8952,600
$4.10+0.02+0.5%$4.08$4.19$4.00104,900
$4.08-0.12-2.9%$4.24$4.31$3.9928,200
$4.20+0.10+2.4%$4.04$4.25$4.0426,300
$4.10-0.05-1.2%$4.13$4.19$3.9451,400
$4.15+0.03+0.7%$4.10$4.305$3.9981,200
$4.12-0.05-1.2%$4.20$4.20$3.9750,200

Splits

1 split · NASDAQ:KLRS · every price before a split is adjusted for it

DayRatioWhat
1-for-23Consolidation
Ticker
NASDAQ:KLRS
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Kalaris Therapeutics, Inc. news

Kalaris Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
13 in the last 12 months · 49 in all · newest Nov 10, 2026 · oldest 2022
Decks
8 decks · latest September 2026

Where Kalaris Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:KLRS · Home listing · This pageNASDAQUnited StatesUSD
BOATS:KLRSBOATSUnited StatesUSD

Valuation

Price/book 0.6× against a median of 3.3×: 3rd lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$51.05M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
0.6×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
0.47

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Kalaris Therapeutics, Inc. · NASDAQ:KLRSUS$30.47M−US$51.05Mn/an/an/a0.6×n/a0.0×0.47
Molecure SA · GPW:MOCUS$31.64MUS$29.58Mn/an/an/a1.3×n/a0.0×n/a
Isofol Medical AB · OMXSTO:ISOFOLUS$31.09MUS$19.84Mn/an/an/a3.3×n/a0.0×n/a
Sareum Holdings plc · LSE:SARUS$31.04MUS$27.79Mn/an/an/a19.9×n/a0.0×n/a
Filana Therapeutics, Inc. · NASDAQ:FLNAUS$30.98M−US$16.01Mn/an/an/a0.5×n/a0.0×1.25
Caribou Biosciences, Inc. · NASDAQ:CRBUUS$30.71M−US$37.75Mn/a−4.0×n/a0.4×n/a0.3×1.87
Avecho Biotechnology Limited · ASX:AVEUS$30.70MUS$26.48Mn/a32.3×n/a24.3×−356.8%0.1×n/a
Pacific Software, Inc. · OTC:PFSFUS$29.86MUS$38.10Mn/an/an/an/an/an/a1.57
NextCure, Inc. · NASDAQ:NXTCUS$29.53MUS$20.81Mn/an/an/a5.4×n/a0.0×1.85
NurExone Biologic Inc · TSXV:NRXUS$29.53MUS$28.52Mn/an/an/a23.3×n/a0.0×0.00
BioHarvest Sciences, Inc. · NASDAQ:BHSTUS$29.47MUS$34.54Mn/a1.0×n/a1.8×−34.7%1.0×0.43
Median of the othersUS$30.71MUS$27.13M1.0×3.3×−195.7%0.0×1.41

Forecasts

5 strong buy · 2 buy · 1 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
18.80 USD · Analysts' mean
EPS, year to Dec 2026
-1.92 · 4 analysts

Team and board

Officers

OfficerRole
Andrew OxtobyCEO & Director
Liisa BaykoCFO
Jill PorterSVP CMC
Kristine CurtissSVP Clinical
Nancy DavisVP Clinical Operations
Mike DybbsDirector & Co-founder
Napoleone FerraraDirector & Co-Founder
Srinivas AkkarajuDirector & Co-founder

Board

DirectorRole
Andrew OxtobyCEO & Director
Anthony AdamisDirector
Laurie KeatingDirector
Leone PattersonDirector
Mike DybbsDirector & Co-founder
Napoleone FerraraDirector & Co-Founder
Srinivas AkkarajuDirector & Co-founder

Events

QuarterResultsShare move
Q3 2026Nov 10, 2026 · Before open−18.7%
Q2 2026Aug 11, 2026 · Before open+0.8%
Q1 2026May 12, 2026 · Before open+1.3%
Q4 2025Mar 17, 2026−14.5%
Q3 2025Nov 12, 2025 · Before open−2.2%
Q2 2025Aug 13, 2025 · Before open−8.4%
Q1 2025May 14, 2025 · Before open+4.0%
Q4 2024Feb 12, 2025+1.0%
Q3 2024Nov 29, 2024−1.9%
Q2 2024Aug 1, 2024+3.9%
All 20 quarters
QuarterResultsShare move
Q1 2024May 2, 2024−1.5%
Q4 2023Feb 8, 2024+7.1%
Q3 2023Nov 2, 2023+9.1%
Q2 2023Aug 3, 2023+3.0%
Q1 2023May 4, 2023+14.3%
Q4 2022Feb 15, 2023−6.1%
Q3 2022Nov 3, 2022+0.8%
Q2 2022Aug 4, 2022+33.6%
Q1 2022May 5, 2022+0.4%
Q4 2021Feb 10, 2022+2.3%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck56 slidesSeptember 2026
Investor Presentation (July 2026)Investor deck57 slidesJul 17, 2026
Investor Presentation (March 2026)Investor deck58 slidesMar 9, 2026
Technical Presentation (December 2025)Technical30 slidesDec 17, 2025
Technical Presentation (December 2025)Technical41 slidesDecember 2025
American Society of Retina Specialists Annual Meeting (December 2025)Conference11 slidesDecember 2025
Allovir — Merger or Acquisition (December 2024)Merger or acquisition39 slidesDec 9, 2024
Merger or Acquisition (November 2024)Merger or acquisition39 slidesNov 25, 2024

Open Decks

Financings

RaiseDate
Private placement of common stock and pre-funded warrants
Announced: about US$50M · US$10 a share · Morgan Stanley +2
Dealers: Morgan Stanley (co-lead), Leerink Partners (co-lead), William Blair
Buyers: ADAR1 Capital Management; Coastlands Capital; Invus; RTW Investments; Samsara BioCapital; Woodline Partners LP
Use of proceeds: Advance clinical development of TH103 for neovascular AMD, working capital and general corporate purposes
Dec 17, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as Allovir, Inc. Priced at US$17.00 a share on Jul 29, 2020.

Price
US$17.00 a share
Shares offered
16,250,000 shares of common stock
Offering size
US$276.3 million
Underwriters' option
Up to 2,437,500 more shares
Underwriters
MORGAN STANLEY, J.P. MORGAN, SVB LEERINK, PIPER SANDLER · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceJun 3, 2020
Filed publiclyJul 6, 2020
Amended onceJul 23, 2020
Shares registered with an exchangeJul 27, 2020
Declared effective by the SECJul 29, 2020
Final prospectus, with the priceJul 30, 2020

Open IPO · From the cover of the final prospectus (424B4) filed Jul 30, 2020

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue0000165.0K1.14M
Cost of revenue13.0K1.12M73.0K
Gross profit-13.0K-1.12M-73.0K
Research and development30.8M45.0M133.1M118.9M120.7M49.7M16.2M1.70M
Selling, general and administrative15.4M6.69M1.76M2.24M
Operating income-46.2M-51.7M-199.9M-171.2M-169.8M-71.3M-26.7M-3.60M
Depreciation and amortization13.0K0398.0K723.0K189.0K73.0K19.0K
EBITDA-46.1M-51.7M-199.5M-170.5M-169.6M-71.2M-26.7M
Interest expense1.44M2.70M687.0K235.0K
Income before tax-43.4M-69.2M-190.5M-169.0M-171.0M-69.8M-23.8M-2.43M
Income tax00-126.0K-265.0K1.01M
Net income-43.4M-69.2M-190.4M-168.7M-172.0M-69.8M-23.8M-2.43M
Earnings per share, basic-2.85-51.77-42.09-2.20-2.74-2.59-18.54-0.86
Earnings per share, diluted-2.85-51.77-42.09-2.20-2.74-2.59-18.54

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents98.1M1.64M90.1M106.1M201.7M122.7M61.1M25.0M
Short-term investments19.9M093.8M127.7M46.5M233.7M65.0M
Receivables50.0K450.0K560.0K302.0K
Current assets118.8M2.61M187.6M243.1M253.3M361.3M127.3M25.3M
Property, plant and equipment930.0K1.55M812.0K350.0K
Total assets121.7M6.16M190.8M277.1M286.6M370.8M139.4M25.3M
Accounts payable1.28M1.56M6.76M3.00M8.36M963.0K630.0K153.0K
Current liabilities9.71M24.7M28.4M24.3M37.9M12.3M9.11M3.74M
Long-term debt3.25M
Total debt1.45M3.25M30.1M8.69M11.8M
Total liabilities42.9M56.8M45.0M52.6M61.3M17.8M17.8M3.74M
Shareholders' equity78.8M-96.6M-45.0M224.5M225.3M353.1M-51.5M21.6M
Shares outstanding22.9M1.36M4.96M93.1M63.6M61.9M2.10M2.83M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations-38.4M-20.7M-124.5M-142.1M-106.3M-60.8M-20.2M1.94M
Capital spending-200.0K000-26.0K-235.0K-339.0K0
Free cash flow-38.6M-67.7M-14.1M-9.78M-106.3M-61.0M-20.5M1.94M
Cash from investing-19.7M95.0M38.0M-80.5M186.0M-169.5M-64.6M
Cash from financing155.0M19.1M70.5M127.0M232.0K292.0M120.9M22.9M
Share buybacks-10.0M
Change in cash96.9M-1.53M-16.0M-95.6M79.9M61.6M36.1M25.0M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 10, 2026Quarterly reportSEC
8-K · Current reportNov 10, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeOct 26, 2026Big-stake noticeSEC
4 · Change in ownershipAug 28, 2026Insider tradeSEC
10-Q · Quarterly reportAug 11, 2026Quarterly reportSEC
8-K · Current reportAug 11, 2026ResultsSEC
4 · Change in ownershipAug 3, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 3, 2026Insider tradeSEC
3 · Initial statement of ownershipJul 27, 2026Insider tradeSEC
4 · Change in ownershipJul 20, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
3 · Initial statement of ownershipJul 20, 2026Insider tradeSEC
8-K · Current reportJul 20, 2026Management or board changeSEC
8-K · Current reportJul 17, 2026Current reportSEC
8-K · Current reportJul 6, 2026Management or board changeSEC
4 · Change in ownershipJun 4, 2026Insider tradeSEC
4 · Change in ownershipJun 4, 2026Insider tradeSEC
4 · Change in ownershipJun 4, 2026Insider tradeSEC
4 · Change in ownershipJun 4, 2026Insider tradeSEC
4 · Change in ownershipJun 4, 2026Insider tradeSEC
4 · Change in ownershipJun 4, 2026Insider tradeSEC
4 · Change in ownershipJun 4, 2026Insider tradeSEC
8-K · Current reportJun 4, 2026Meeting outcomeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 22, 2026Big-stake noticeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
10-Q · Quarterly reportMay 12, 2026Quarterly reportSEC
8-K · Current reportMay 12, 2026ResultsSEC
ARS · Annual report to shareholdersApr 24, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 24, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 24, 2026Meeting noticeSEC
EFFECT · Notice that a registration is effectiveApr 14, 2026Other filingsSEC
EFFECT · Notice that a registration is effectiveApr 14, 2026Other filingsSEC
424B3 · ProspectusApr 13, 2026Offer documentSEC
424B3 · ProspectusApr 13, 2026Offer documentSEC
8-K · Current reportApr 10, 2026Management or board changeSEC
CORRESP · Letter to the SECApr 9, 2026Other filingsSEC
CORRESP · Letter to the SECApr 9, 2026Other filingsSEC
UPLOAD · Letter from the SECApr 8, 2026Other filingsSEC
UPLOAD · Letter from the SECApr 8, 2026Other filingsSEC
S-3 · Registration statementApr 3, 2026Offer documentSEC
S-3 · Registration statementApr 3, 2026Offer documentSEC
4 · Change in ownershipMar 23, 2026Insider tradeSEC
144 · Notice of proposed saleMar 20, 2026Other filingsSEC
4 · Change in ownershipMar 20, 2026Insider tradeSEC
4 · Change in ownershipMar 20, 2026Insider tradeSEC
4 · Change in ownershipMar 20, 2026Insider tradeSEC
S-8 · Registration statement for employee plansMar 17, 2026Offer documentSEC
10-K · Annual reportMar 17, 2026Annual reportSEC
8-K · Current reportMar 17, 2026ResultsSEC
8-K · Current reportMar 9, 2026Current reportSEC
4 · Change in ownershipFeb 17, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedDec 22, 2025Big-stake noticeSEC
4 · Change in ownershipDec 22, 2025Insider tradeSEC
8-K · Current reportDec 18, 2025Material contractSEC
8-K · Current reportDec 17, 2025Current reportSEC
10-Q · Quarterly reportNov 12, 2025Quarterly reportSEC
8-K · Current reportNov 12, 2025ResultsSEC
4 · Change in ownershipNov 3, 2025Insider tradeSEC
3 · Initial statement of ownershipNov 3, 2025Insider tradeSEC
8-K · Current reportNov 3, 2025Management or board changeSEC
10-Q · Quarterly reportAug 13, 2025Quarterly reportSEC
8-K · Current reportAug 13, 2025Meeting outcomeSEC
8-K · Current reportAug 13, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 29, 2025Big-stake noticeSEC
ARS · Annual report to shareholdersJul 1, 2025Annual reportSEC
DEFA14A · Additional proxy materialJul 1, 2025Meeting noticeSEC
DEF 14A · Proxy statementJul 1, 2025Meeting noticeSEC
8-K · Current reportJun 20, 2025Current reportSEC
S-8 · Registration statement for employee plansJun 4, 2025Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 14, 2025Quarterly reportSEC
8-K · Current reportMay 14, 2025ResultsSEC
8-K · Current reportApr 16, 2025Management or board changeSEC
4 · Change in ownershipApr 11, 2025Insider tradeSEC
4 · Change in ownershipApr 11, 2025Insider tradeSEC
4 · Change in ownershipApr 11, 2025Insider tradeSEC
4 · Change in ownershipApr 11, 2025Insider tradeSEC
4 · Change in ownershipApr 11, 2025Insider tradeSEC
4 · Change in ownershipApr 11, 2025Insider tradeSEC
4 · Change in ownershipApr 11, 2025Insider tradeSEC
4 · Change in ownershipApr 11, 2025Insider tradeSEC
4 · Change in ownershipApr 11, 2025Insider tradeSEC
4 · Change in ownershipApr 11, 2025Insider tradeSEC
4 · Change in ownershipApr 11, 2025Insider tradeSEC
3 · Initial statement of ownershipApr 4, 2025Insider tradeSEC
8-K · Current reportApr 4, 2025Management or board changeSEC
4 · Change in ownershipMar 27, 2025Insider tradeSEC
3/A · Initial statement of ownership, amendedMar 26, 2025Insider tradeSEC
SCHEDULE 13D · Big-stake noticeMar 25, 2025Big-stake noticeSEC
3 · Initial statement of ownershipMar 25, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 20, 2025Big-stake noticeSEC
4 · Change in ownershipMar 18, 2025Insider tradeSEC
4 · Change in ownershipMar 18, 2025Insider tradeSEC
4 · Change in ownershipMar 18, 2025Insider tradeSEC
4 · Change in ownershipMar 18, 2025Insider tradeSEC
4 · Change in ownershipMar 18, 2025Insider tradeSEC
4 · Change in ownershipMar 18, 2025Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2025Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2025Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2025Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2025Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2025Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2025Insider tradeSEC
3 · Initial statement of ownershipMar 18, 2025Insider tradeSEC
8-K · Current reportMar 18, 2025ResultsSEC
8-K · Current reportMar 12, 2025Management or board changeSEC
10-K · Annual reportMar 7, 2025Annual reportSEC
424B3 · ProspectusFeb 28, 2025Offer documentSEC
4 · Change in ownershipFeb 24, 2025Insider tradeSEC
4 · Change in ownershipFeb 24, 2025Insider tradeSEC
4 · Change in ownershipFeb 24, 2025Insider tradeSEC
144 · Notice of proposed saleFeb 24, 2025Other filingsSEC
144 · Notice of proposed saleFeb 24, 2025Other filingsSEC
144 · Notice of proposed saleFeb 24, 2025Other filingsSEC
SEC STAFF LETTERFeb 19, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveFeb 11, 2025Other filingsSEC
424B3 · ProspectusFeb 10, 2025Offer documentSEC
CORRESP · Letter to the SECFeb 6, 2025Other filingsSEC
CORRESP · Letter to the SECFeb 3, 2025Other filingsSEC
S-4/A · Registration statement, amendedFeb 3, 2025Offer documentSEC
UPLOAD · Letter from the SECJan 28, 2025Other filingsSEC
4 · Change in ownershipJan 27, 2025Insider tradeSEC
4 · Change in ownershipJan 27, 2025Insider tradeSEC
4 · Change in ownershipJan 27, 2025Insider tradeSEC
144 · Notice of proposed saleJan 24, 2025Other filingsSEC
144 · Notice of proposed saleJan 24, 2025Other filingsSEC
144 · Notice of proposed saleJan 24, 2025Other filingsSEC
CORRESP · Letter to the SECJan 17, 2025Other filingsSEC
S-4/A · Registration statement, amendedJan 17, 2025Offer documentSEC
425Jan 15, 2025Other filingsSEC
8-K · Current reportJan 15, 2025Current reportSEC
4 · Change in ownershipJan 13, 2025Insider tradeSEC
4 · Change in ownershipJan 13, 2025Insider tradeSEC
4 · Change in ownershipJan 13, 2025Insider tradeSEC
144 · Notice of proposed saleJan 10, 2025Other filingsSEC
144 · Notice of proposed saleJan 10, 2025Other filingsSEC
144 · Notice of proposed saleJan 10, 2025Other filingsSEC
425Jan 10, 2025Other filingsSEC
8-K · Current reportJan 10, 2025Current reportSEC
425Jan 10, 2025Other filingsSEC
SEC STAFF LETTERJan 10, 2025Other filingsSEC
8-K · Current reportJan 10, 2025Meeting outcomeSEC
UPLOAD · Letter from the SECJan 6, 2025Other filingsSEC
425Dec 20, 2024Other filingsSEC
8-K · Current reportDec 20, 2024Management or board changeSEC
4 · Change in ownershipDec 11, 2024Insider tradeSEC
S-4 · Registration statementDec 9, 2024Offer documentSEC
425Dec 6, 2024Other filingsSEC
DEF 14A · Proxy statementDec 6, 2024Meeting noticeSEC
PRE 14A · Preliminary proxy statementNov 26, 2024Meeting noticeSEC
4 · Change in ownershipNov 20, 2024Insider tradeSEC
4 · Change in ownershipNov 20, 2024Insider tradeSEC
4 · Change in ownershipNov 20, 2024Insider tradeSEC
4 · Change in ownershipNov 20, 2024Insider tradeSEC
144 · Notice of proposed saleNov 19, 2024Other filingsSEC
144 · Notice of proposed saleNov 19, 2024Other filingsSEC
144 · Notice of proposed saleNov 19, 2024Other filingsSEC
144 · Notice of proposed saleNov 19, 2024Other filingsSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
425Nov 8, 2024Other filingsSEC
425Nov 8, 2024Other filingsSEC
425Nov 8, 2024Other filingsSEC
425Nov 8, 2024Other filingsSEC
425Nov 8, 2024Other filingsSEC
425Nov 8, 2024Other filingsSEC
8-K · Current reportNov 8, 2024Material contractSEC
4 · Change in ownershipNov 6, 2024Insider tradeSEC
4 · Change in ownershipNov 6, 2024Insider tradeSEC
4 · Change in ownershipNov 6, 2024Insider tradeSEC
4 · Change in ownershipNov 6, 2024Insider tradeSEC
144 · Notice of proposed saleNov 5, 2024Other filingsSEC
144 · Notice of proposed saleNov 5, 2024Other filingsSEC
144 · Notice of proposed saleNov 5, 2024Other filingsSEC
144 · Notice of proposed saleNov 5, 2024Other filingsSEC
4 · Change in ownershipOct 23, 2024Insider tradeSEC
4 · Change in ownershipOct 23, 2024Insider tradeSEC
4 · Change in ownershipOct 23, 2024Insider tradeSEC
4 · Change in ownershipOct 23, 2024Insider tradeSEC
144 · Notice of proposed saleOct 22, 2024Other filingsSEC
144 · Notice of proposed saleOct 22, 2024Other filingsSEC
144 · Notice of proposed saleOct 22, 2024Other filingsSEC
144 · Notice of proposed saleOct 21, 2024Other filingsSEC
144 · Notice of proposed saleOct 21, 2024Other filingsSEC
144 · Notice of proposed saleOct 21, 2024Other filingsSEC
144 · Notice of proposed saleOct 21, 2024Other filingsSEC
SC 13G · Big-stake noticeOct 11, 2024Big-stake noticeSEC
4 · Change in ownershipOct 4, 2024Insider tradeSEC
4 · Change in ownershipOct 4, 2024Insider tradeSEC
4 · Change in ownershipOct 4, 2024Insider tradeSEC
4 · Change in ownershipOct 4, 2024Insider tradeSEC
144 · Notice of proposed saleOct 3, 2024Other filingsSEC
144 · Notice of proposed saleOct 3, 2024Other filingsSEC
144 · Notice of proposed saleOct 3, 2024Other filingsSEC
144 · Notice of proposed saleOct 3, 2024Other filingsSEC
4 · Change in ownershipAug 22, 2024Insider tradeSEC
144 · Notice of proposed saleAug 21, 2024Other filingsSEC
4 · Change in ownershipAug 20, 2024Insider tradeSEC
4 · Change in ownershipAug 20, 2024Insider tradeSEC

This page holds 200 of 701 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Kalaris Therapeutics, Inc.’s releases · as of Dec 17, 2025

Common shares
23,804,981
Fully diluted
23,804,981

Fully diluted

LineShares
Common shares23,804,981

Share count over time

CountShares
Nov 22, 202623,804,981

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueChange vs Jun 30Filed
Samsara Biocapital, LLC12.9M54.1%US$37.2MNo changeNov 16, 2026
Rtw Investments, LP1.3M5.5%US$3.76MNo changeNov 16, 2026
Alyeska Investment Group, L.P.473K2.0%US$1.37M−100KNov 16, 2026
Vanguard379K1.6%US$1.1M−86,410Nov 13, 2026
Siren, L.L.C.357K1.5%US$1.03M−79,239Nov 12, 2026
Ikarian Capital, LLC248K1.0%US$717K−112KNov 16, 2026
Renaissance Technologies177K0.74%US$511K+27,512Nov 12, 2026
Verdad Advisers, LP140K0.59%US$405K+59,935Nov 16, 2026
UBS110K0.46%US$318K−152KNov 10, 2026
Raymond James Financial Inc101K0.43%US$293K+4,332Nov 12, 2026
Show 50 holders
HolderSharesOf the companyValueChange vs Jun 30Filed
WHI TRUST Co LLC97,4930.41%US$282KNo changeNov 12, 2026
Woodline Partners LP90,0000.38%US$260K−10,000Nov 16, 2026
Geode Capital78,8590.33%US$228K−35,178Nov 6, 2026
Boothbay Fund Management, LLC63,6230.27%US$184K−28,638Nov 16, 2026
ADAR1 Capital Management, LLC60,0000.25%US$173K−40,000Nov 16, 2026
BlackRock58,6190.25%US$169K+4,177Nov 13, 2026
State Street51,2100.22%US$148K+24,700Nov 12, 2026
Fortis Capital Advisors, LLC40,0000.17%US$116KNo changeNov 9, 2026
Belpointe Asset Management LLC40,0000.17%US$116KNo changeNov 9, 2026
Goldman Sachs39,6160.17%US$114K+23,562Nov 16, 2026
Citadel39,2190.16%US$113K−56,553Nov 16, 2026
Connor, Clark & Lunn Investment Management Ltd.35,6780.15%US$103K+5,671Nov 10, 2026
Stonepine Capital Management, LLC33,8420.14%US$97,803+3,720Nov 13, 2026
Morgan Stanley26,7730.11%US$77,374−45,553Nov 13, 2026
Northern Trust25,8330.11%US$74,657−6Nov 16, 2026
Hrt Financial LP25,5600.11%US$73,000+11,837Nov 13, 2026
Velan Capital Investment Management LP25,0000.11%US$72,250No changeNov 16, 2026
WealthTrust Asset Management, LLC23,6040.10%US$68,214+3,188Oct 22, 2026
Quadrature Capital Ltd23,2870.10%US$67,299+6,760Nov 13, 2026
Empowered Funds, LLC22,5000.09%US$65,025NewNov 13, 2026
Bridgeway Capital Management, LLC22,5000.09%US$65,025−10,000Nov 16, 2026
Jane Street19,5940.08%US$56,627NewNov 12, 2026
Squarepoint Ops LLC18,9470.08%US$54,757−19,828Nov 9, 2026
RBF Capital, LLC17,3910.07%US$50,260No changeNov 13, 2026
Dimensional15,9580.07%US$46,122No changeNov 4, 2026
XTX Topco Ltd14,7260.06%US$42,558NewNov 16, 2026
Nano Cap New Millennium Growth Fund L P14,0000.06%US$40,460+1,500Nov 13, 2026
Independent Advisor Alliance12,6250.05%US$36,486−5,500Nov 10, 2026
Fidelity7,8060.03%US$22,559No changeNov 10, 2026
Federation des caisses Desjardins du Quebec6,0000.03%US$17,340NewNov 16, 2026
Nuveen4,6390.02%US$13,453NewNov 10, 2026
Caitong International Asset Management Co., Ltd1,559<0.01%US$4,506+1,552Oct 29, 2026
Tower Research Capital LLC (TRC)838<0.01%US$2,422−1,722Nov 16, 2026
Strengthening Families & Communities, LLC268<0.01%US$775No changeOct 21, 2026
JPMorgan50<0.01%US$145No changeNov 12, 2026
BNP Paribas46<0.01%US$133−6Nov 12, 2026
Steward Partners Investment Advisory, LLC21<0.01%US$61−2,194Nov 13, 2026
Barclays17<0.01%US$49−286Nov 6, 2026
RBC14<0.01%+2Nov 16, 2026
Harbour Investments, Inc.13<0.01%US$38No changeNov 9, 2026

This page holds 50 of 52 holders. Open Shareholders

Funds

HolderSharesOf the companyValueChangeAs of
Vanguard Total Stock Market Index Fund255K1.1%US$1.04M+78,610Jun 30, 2026
Vanguard Extended Market Index Fund137K0.58%US$559K+64,754Jun 30, 2026
Fidelity Extended Market Index Fund34,5740.15%US$182K+596May 31, 2026
Ultra-Small Company Market Fund32,5000.14%US$132K+10,000Jun 30, 2026
iShares Micro-Cap ETF25,9240.11%US$106K+17,225Jun 30, 2026
Fidelity Nasdaq Composite Index Fund16,8290.07%US$88,689No changeMay 31, 2026
Fidelity Total Market Index Fund9,8850.04%US$52,094No changeMay 31, 2026
Fidelity Series Total Market Index Fund9,5750.04%US$50,460+716May 31, 2026
Goldman Sachs Absolute Return Tracker Fund8,0200.03%US$32,641−410Jun 30, 2026
VIP Disciplined Small Cap Portfolio7,8060.03%US$31,770No changeJun 30, 2026
All 19 holders
HolderSharesOf the companyValueChangeAs of
Vanguard Balanced Index Fund6,0020.03%US$24,428No changeJun 30, 2026
Dimensional US Core Equity 1 ETF3,2960.01%US$11,569NewJul 31, 2026
U.S. Vector Equity Portfolio2,7500.01%US$9,653NewJul 31, 2026
Dimensional U.S. Core Equity 2 ETF2,6140.01%US$9,175NewJul 31, 2026
1290 VT Micro Cap Portfolio1,725<0.01%US$7,021+1,117Jun 30, 2026
Victory Extended Market Index Fund911<0.01%US$3,198NewJul 31, 2026
LVIP Dimensional U.S. Core Equity 2 Fund135<0.01%US$549No changeJun 30, 2026
JNL/DFA U.S. Small Cap Fund79<0.01%US$322No changeJun 30, 2026
Knights of Columbus U.S. ALL CAP INDEX FUND47<0.01%US$165+3Jul 31, 2026

Insider trades

InsiderTradeSharesPriceValueDate
Srinivas Akkaraju
10% owner
Buy244,300USD 4.83US$1.18MMay 20, 2026

Big stakes

HolderStakeSharesDate
Srinivas Akkaraju54.20%12.9MMay 20, 2026
Rtw Investments, LP5.70%1.3MDec 31, 2025
Coastlands Capital LP5.69%1.36MOct 19, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Srinivas Akkaraju
Other companies: Alumis Inc. (Founder and Managing Member, Samsara BioCapital · Since at least Jun 27, 2024); vTv Therapeutics Inc. (Director · Since at least Feb 23, 2024); Mineralys Therapeutics, Inc. (Board Member · Since at least Feb 9, 2023); Scholar Rock Holding Corporation (Director · Since at least Jul 26, 2022); Jiya Acquisition Corp (Director · Nov 18, 2020 – Sep 23, 2022 · Past); Aduro Biotech Inc (Director · Oct 5, 2020 – Aug 11, 2023 · Past); Principia Biopharma Inc (Director · Sep 13, 2018 – Sep 18, 2018 · Past); Syros Pharmaceuticals, Inc. (Director · Jun 8, 2017 – Sep 16, 2024 · Past); aTyr Pharma, Inc. (Director · May 6, 2015 – May 9, 2017 · Past); ZS Pharma Inc (Director · Jun 23, 2014 – Dec 17, 2015 · Past); Aravive Inc (Director · Mar 20, 2014 – Dec 2, 2019 · Past); Intercept Pharmaceuticals Inc (Director · Oct 10, 2012 – Nov 8, 2023 · Past); Synageva BioPharma Corp (Director · Nov 2, 2011 – Mar 19, 2012 · Past); Barrier Therapeutics Inc (Director · Jun 6, 2007 – Aug 5, 2008 · Past); Pharmos Corp (Director · Oct 25, 2006 – Jan 15, 2009 · Past); Seagen Inc (Director · Apr 6, 2006 – May 15, 2020 · Past)
Director · Since at least Mar 18, 2025
Shawn Tomasello
Other companies: Cabaletta Bio, Inc. (Independent Director, former CCO of Kite Pharma, Inc. · Since at least Jul 21, 2023); 4D Molecular Therapeutics, Inc. (Director · Since at least Dec 10, 2020); Gamida Cell Ltd (Director · Jan 1, 2022 – Jan 31, 2024 · Past); Tcr2 Therapeutics Inc (Director · Feb 3, 2021 – Jun 1, 2023 · Past); Abeona Therapeutics Inc. (Director · Apr 15, 2020 – May 20, 2020 · Past); Principia Biopharma Inc (Director · Aug 29, 2019 – Sep 28, 2020 · Past); UroGen Pharma Ltd. (Director · Jan 1, 2019 – Jun 7, 2021 · Past); Kite Pharma Inc (Chief Commercial Officer · Dec 17, 2015 – Oct 3, 2017 · Past); Diplomat Pharmacy Inc (Director · Oct 6, 2015 – Feb 10, 2020 · Past); Pharmacyclics Inc (Chief Commercial Officer · Aug 18, 2014 – May 26, 2015 · Past)
Director · Mar 29, 2022 – Jun 6, 2024 · Past
Ansbert Gadicke
Other companies: Cullinan Therapeutics, Inc. (Director · Jan 7, 2021 – Jun 22, 2022 · Past); Iteos Therapeutics Inc (Director · Jul 23, 2020 – Jul 28, 2020 · Past); Tcr2 Therapeutics Inc (Director · Feb 13, 2019 – Jun 1, 2023 · Past); Chiasma Inc (Director · Jul 15, 2015 – Jun 9, 2016 · Past); Verastem, Inc. (Director · Jan 26, 2012 – Mar 6, 2012 · Past); Radius Health, Inc. (Director · May 17, 2011 – Feb 17, 2017 · Past)
Director · Jul 29, 2020 – Jul 28, 2022 · Past
Leone Patterson
Other companies: Zymeworks Inc. (EVP, Chief Bus & Fin Officer · Since at least Sep 1, 2024); Nkarta, Inc. (Member of Board of Directors · Since at least Jul 9, 2020); Climb Bio, Inc. (Director · Aug 9, 2021 – May 19, 2022 · Past); Tenaya Therapeutics, Inc. (Chief Fin. and Bus. Officer · Jul 29, 2021 – Feb 23, 2024 · Past); Adverum Biotechnologies Inc (President and CFO · Jun 15, 2016 – Feb 16, 2021 · Past); Paratek Pharmaceuticals Inc (Vice President, CFO · Jun 25, 2012 – Oct 30, 2014 · Past)
Director · Since at least Apr 3, 2025
Laurie Keating
Other companies: PepGen Inc. (Director · Since at least May 5, 2022); Immuneering Corporation (Director · Since at least Jul 29, 2021); Imago Biosciences Inc (Director · Nov 17, 2021 – Jan 11, 2023 · Past); Alnylam Pharmaceuticals, Inc. (EVP, Chief Legal Officer · Jan 11, 2021 – Aug 5, 2021 · Past); Millennium Pharmaceuticals Inc (SVP and General Counsel · Mar 3, 2006 – May 14, 2008 · Past)
Director · Since at least Jul 6, 2026
David L. Hallal
Other companies: Iteos Therapeutics Inc (Director · Since at least Jul 23, 2020); Scholar Rock Holding Corporation (Chairman and Chief Executive Officer · Since at least May 23, 2018); Seer, Inc. (Director · Dec 3, 2020 – Jun 12, 2024 · Past); Alexion Pharmaceuticals Inc (CEO, Director · Feb 23, 2009 – Aug 8, 2016 · Past)
Director · Since at least Jul 29, 2020
Michael Dybbs
Other companies: SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Nkarta, Inc. (Director · Since at least Jul 9, 2020); Sutro Biopharma, Inc. (Member, Board of Directors · Since at least Sep 26, 2018); Dimension Therapeutics (Director · Oct 21, 2015 – Nov 7, 2017 · Past)
Director · Since at least Mar 18, 2025
Vikas Sinha
Other companies: Scholar Rock Holding Corporation (Chief Financial Officer · Since at least Apr 27, 2025); Verona Pharma plc (Director · Since at least Jan 1, 2021); BCLS Acquisition Corp (Director · Oct 22, 2020 – Oct 22, 2020 · Past); Alexion Pharmaceuticals Inc (EVP & CFO · Jul 12, 2013 – Aug 8, 2016 · Past)
See Remarks, Director · Jul 29, 2020 – Feb 21, 2025 · Past
Jeff Bornstein
Other companies: Eos Energy Enterprises, Inc. (Director · Since at least Sep 7, 2022); SpringBig Holdings, Inc. (Director · Feb 11, 2021 – Feb 11, 2021 · Past); GE Aerospace (Vice Chairman · Jul 1, 2013 – Nov 6, 2017 · Past)
Director · Jul 29, 2020 – Jun 6, 2024 · Past
Andrew Oxtoby
Other companies: Aduro Biotech Inc (Chief Commercial Officer · Feb 15, 2023 – Aug 11, 2023 · Past); Aimmune Therapeutics Inc (Chief Commercial Officer · Jan 22, 2019 – Oct 10, 2020 · Past)
CEO & Director · Since at least Mar 18, 2025
All 31 people
PersonSeat
Cintia Piccina
Other companies: Autolus Therapeutics plc (Senior Vice President, General Manager US · Since at least Mar 18, 2026); Adaptimmune Therapeutics PLC (Chief Commercial Officer · Jan 31, 2022 – Feb 20, 2025 · Past)
Chief Commercial Officer · Jun 12, 2023 – Jul 3, 2023 · Past
Matthew Gall
Other companies: Tango Therapeutics, Inc. (Chief Financial Officer · Since at least Apr 15, 2026); Iteos Therapeutics Inc (Chief Financial Officer · Since at least Jul 23, 2020)
Chief Financial Officer · Since at least Nov 3, 2025
Morana Jovan-Embiricos
Other companies: Cullinan Therapeutics, Inc. (Director · Jan 7, 2021 – Sep 16, 2021 · Past); Tcr2 Therapeutics Inc (Director · Feb 13, 2019 – Feb 19, 2019 · Past)
Director · Since at least Jul 29, 2020
Agustin Melian
Other companies: Forma Therapeutics Holdings Inc (EVP, Research & Development · Jul 11, 2022 – Oct 14, 2022 · Past)
Chief Medical Officer · Jul 29, 2020 – Oct 4, 2021 · Past
Ann M Leen
Other companies: Marker Therapeutics, Inc. (Chief Scientific Officer · Dec 21, 2018 – Feb 15, 2020 · Past)
Chief Scientific Officer · Jul 29, 2020 – Aug 16, 2022 · Past
Anthony Adamis
Other companies: EyePoint, Inc. (Director · Jun 23, 2022 – Jun 23, 2024 · Past)
Director · Since at least Nov 8, 2024
Brett R Hagen
Other companies: Kineta Inc. (See Remarks · Aug 4, 2016 – Apr 3, 2017 · Past)
Chief Accounting Officer · Since at least Jul 29, 2020
Diana Brainard
Other companies: Nektar Therapeutics (Director · Since at least Nov 11, 2021)
Chief Executive Officer, Director · Jul 29, 2020 – Nov 19, 2024 · Past
Edward Miller
Other companies: Alexion Pharmaceuticals Inc (SVP, Chief Compliance Officer · Sep 9, 2016 – Feb 27, 2017 · Past)
General Counsel · Jul 29, 2020 – Feb 21, 2025 · Past
Jeroen B Van Beek
Other companies: Tricida Inc (Chief Comm Officer and Sr VP · Jun 27, 2018 – Jul 2, 2018 · Past)
Chief Commercial Officer · Jul 29, 2020 – Nov 16, 2022 · Past
John Robert Wilson
Other companies: Marker Therapeutics, Inc. (Director · Oct 17, 2018 – Jun 6, 2023 · Past)
Director · Jul 29, 2020 – May 25, 2021 · Past
Juan F. Vera
Other companies: Marker Therapeutics, Inc. (Chief Executive Officer & Co-Founder, Marker Therapeutics · Since at least Oct 17, 2018)
Director · Jul 29, 2020 – Jun 6, 2024 · Past
Mike Dybbs
Other companies: Nkarta, Inc. (Director · Since at least Nov 4, 2026)
Director & Co-founder · Since at least Nov 8, 2024
Napoleone Ferrara
Other companies: TuHURA Biosciences, Inc. (Director · Apr 30, 2019 – Jun 26, 2020 · Past)
Director & Co-Founder · Since at least Mar 18, 2025
Samir Chandrakant Patel
Other companies: IVERIC bio Inc (President, Director · Sep 24, 2013 – Jan 4, 2017 · Past)
Director · Mar 18, 2025 – Apr 10, 2025 · Past
Amy O'Leary VandekopVP, Corporate Controller · Since at least Jul 27, 2026
Derek N AdamsDirector · Mar 1, 2023 – Jun 6, 2024 · Past
Ercem AtillasoySee Remarks · Jul 29, 2020 – Oct 20, 2022 · Past
Liisa BaykoCFO · Since at least Jul 20, 2026
Malcolm BrennerDirector · Jul 29, 2020 – Jun 6, 2024 · Past
Matthew FeinsodChief Medical Officer · Since at least Mar 18, 2025

Open People

Log in to ask 6ix AI your own questions about Kalaris Therapeutics, Inc.